期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution 被引量：2

The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution
原文传递
导出
摘要 Chemotherapy employs chemical substances to interfere with the growth of cancer cells,and is a major treatment strategy in human cancer including acute myeloid leukemia（AML）.Although they often effectively kill fast-dividing tumor cells, Chemotherapy employs chemical substances to interfere with the growth of cancer cells,and is a major treatment strategy in human cancer including acute myeloid leukemia(AML).Although they often effectively kill fast-dividing tumor cells,chemotherapeutic drugs also profoundly
作者 CHEN AiLi YANG JingYi HU ShaoYan WANG Qian-Fei
机构地区 Key Laboratory of Genomic and Precision Medicine The Children's Hospital of Soochow University
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2015年第12期1302-1305,共4页 中国科学（生命科学英文版）
基金 supported by China Ministry of Science and Technology grants(2014CB542001) the Key Research Program of the Chinese Academy of Sciences(Precious Medicine Research in Chinese Population) the National Natural Science Foundation of China(91331111 81425003)
关键词 regimen chemotherapy clonal interfere myeloid dividing subgroup induction clone relapse 白血病 进化策略 化疗 低剂量 克隆 诱导 肿瘤细胞 癌细胞
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol, 2014, 8:1095-1111.
  • 2Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481:506-510.
  • 3Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 2012, 486:537-540.
  • 4Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study. Leukemia, 1995, 9:10-14.
  • 5Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000, 71:238-244.
  • 6Li J, Chen Y, Zhu Y, Zhou J, Xu Y, Li Y, Yu K, Pan L, Wang J, Ding J, Gu J, Zhou S, Shi J, Hong M, Xu J, Pan L, Duan L, Zhang R, Zhang S, Zhu H, Lu H, Liu P, Qiu H, Wu H, Qian S. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget, 2015, 6:6448-6458.
  • 7Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res, 2009, 69:4894-4903.
  • 8Benzekry S, Hahnfeldt P. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. J Theor Biol, 2013, 335:235-244.
  • 9Li SC, Lee KL, Luo J. Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal:implication for new therapies. Stem Cells Dev, 2012, 21:503-506.
  • 10Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leuk Res, 2015, 39:719-729.

同被引文献5

引证文献2

二级引证文献1

Science China(Life Sciences)
2015年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部